A specialized healthcare investor Gilde Healthcare has acquired the leading medical needle manufacturer EUROPIN to form a leading integrated contract manufacturer for tailor-made cannulas and cannula systems. KPMG has acted as a buy-side advisor.
About the deal
EUROPIN, headquartered in Heidelberg (Germany) with a development and production plant in Trenčín (Slovakia), develops and manufactures medical needles, such as pen cannulas and lancet needles for medical and pharmaceutical applications with a focus on injection systems for self-medication in the field of diabetes and hormone therapies. Founded in 1997, EUROPIN has strengthened its market positioning during the last years by evolving its comprehensive product portfolio to become one of the European leaders in its market, with an annual output of more than two billion needles and cannulas
Gilde Healthcare is a specialized healthcare investor managing assets worth more than EUR 1.4 bn. The firm is headquartered in Utrecht (The Netherlands) with local offices in Frankfurt (Germany) and Cambridge (United States). Gilde Healthcare Private Equity participates in profitable lower mid-market healthcare companies based in North-Western Europe. The Private Equity fund targets healthcare providers, suppliers of medical products and service providers in the healthcare market.
The transaction marks the third acquisition in the DACH region by Gilde Healthcare Private Equity in the past 12 months. The investor will combine EUROPIN with its portfolio company Acti-Med, one of the leading manufacturers in the field of medical technology. Acti-Med focuses on tailor-made, highly regulated cannulas and cannula systems for pharmaceutical and medical applications.
By joining forces, EUROPIN and Acti-Med will be able to significantly expand their footprint – in terms of geography as well as breadth and depth of the product portfolio. The group will represent one of the largest contract manufacturers of raw cannulas and cannula systems in Europe.
We are pleased to have a new partner at our side and look forward to the next steps we will jointly pursue. We are convinced that joining forces with Acti-Med will bring great value to both companies and help build a global leader.
We are impressed by EUROPIN's success over the last years and the achievements of the entire management team. There is also a great strategic fit between Acti-Med and EUROPIN.
The year 2021 was an exciting year, in which we already made great strides together with Gilde Healthcare. We look forward to taking the next steps in our joint journey with our new partner EUROPIN.
A joint team of KPMG in Slovakia and KPMG Germany provided buy-side advisory to Acti-Med (portfolio company of Gilde Healthcare) which consisted of financial and tax due diligence as well as SPA assistance on the acquisition of EUROPIN Group.